| cpd00812 | 1283096-66-1 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI |
cpd00813 | 1283096-65-0 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00814 | 1283096-64-9 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00815 | 1283096-63-8 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00816 | 1283096-62-7 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00817 | 1283096-61-6 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | acridone-4-carboxylic acid (4-carboxyacridone) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00818 | 1283096-60-5 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | XRPKT | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00819 | 1283096-59-2 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00820 | 1283096-58-1 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | XRPKT | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00821 | 1283096-57-0 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | XTKPR | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00822 | 1283096-56-9 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00823 | 1283096-55-8 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | XTKPR | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00824 | 1283096-54-7 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | XTKPR | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00825 | 1283096-53-6 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00826 | 1283096-52-5 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00827 | 1283096-51-4 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00828 | 1283096-50-3 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00829 | 1283096-49-0 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00830 | 1283096-48-9 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00831 | 1283096-47-8 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | RPKT | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00832 | 1283096-46-7 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00833 | 1283096-45-6 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00834 | 1283096-44-5 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00835 | 1283096-43-4 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00836 | 1283096-42-3 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPR | 1,4-dihydroxyanthraquinone (quinizarin) derivative | Anticancer therapy, A549 and HL-60 cells) | amide | Kukowska-et.al (2011)
DOI | cpd00837 | 1283096-41-2 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPX | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | cpd00838 | 1283096-40-1 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPX | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | cpd00839 | 1283096-39-8 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPX | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | cpd00840 | 1283096-38-7 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPX | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | cpd00841 | 1283096-37-6 | tuftsin (liberated from the Fc domain of the heavy chain of IgG | TKPX | 2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide | Anticancer therapy, A549 and HL-60 cells) | sulfonamide | Kukowska-et.al (2011)
DOI | 
